OncoMatch/Clinical Trials/NCT06193889
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Is NCT06193889 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including KYV-101 and Standard of Care Treatment for myasthenia gravis.
Treatment: Standard of Care Treatment · Standard lymphodepletion regimen · KYV-101 — A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CHRNA1 autoantibody
Presence of autoantibodies to AChR or MuSK at screening
Required: MUSK autoantibody
Presence of autoantibodies to AChR or MuSK at screening
Prior therapy
Must have received: immunosuppressive or immunomodulatory therapy
Failed treatment with 2 or more immunosuppressive/immunomodulatory therapies, or failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, or IVIG (>4 times/year over ≥12 months) to control symptoms
Cannot have received: anti-CD20 monoclonal antibody (rituximab)
No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening
Cannot have received: anti-CD19 monoclonal antibody
No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening
Cannot have received: FcRn inhibitor
No use of FcRn inhibitors within 4 weeks prior to screening
Cannot have received: gene therapy product
Prior treatment with gene therapy product or cellular immunotherapy (eg, CAR T) requiring vector integration and directed at any target
Cannot have received: cellular immunotherapy
Prior treatment with gene therapy product or cellular immunotherapy (eg, CAR T) requiring vector integration and directed at any target
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Irvine · Orange, California
- Stanford University Medical Center · Palo Alto, California
- University of Miami · Miami, Florida
- Indiana University Health · Indianapolis, Indiana
- Thomas Jefferson University Hospital · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify